# Report: Impact of US Tariffs on Medicines

## Executive Summary
This report analyzes the impact of US tariffs on the global pharmaceutical landscape, focusing on their effects on medicine prices, supply chains, and key trading partners. While the WTO Pharmaceutical Agreement has largely eliminated tariffs on pharmaceuticals among signatory nations, recent US proposals and existing tariffs in some developing countries continue to influence the market. Academic studies suggest that tariffs could lead to increased medicine costs for US consumers and disrupt global supply chains, particularly for generic drugs.

## 执行摘要
本报告分析了美国关税对全球制药业格局的影响，重点关注其对药品价格、供应链和主要贸易伙伴的影响。尽管世贸组织《药品协议》已基本取消了签署国之间药品的关税，但美国最近的提案以及一些发展中国家现有的关税继续影响着市场。学术研究表明，关税可能导致美国消费者药品成本增加，并扰乱全球供应链，特别是仿制药。

## 1. Introduction
The pharmaceutical industry is a globalized sector, with complex supply chains spanning numerous countries. Tariffs, while often used as a tool for trade policy, can have significant repercussions on the availability, accessibility, and affordability of essential medicines. This report delves into the specific tariffs imposed by the United States on pharmaceutical products and active pharmaceutical ingredients (APIs), examining their implications for both the US domestic market and international trade.

## 1. 引言
制药业是一个全球化产业，其复杂的供应链遍布多个国家。关税，作为贸易政策的工具，可能对基本药物的可获得性、可及性和可负担性产生重大影响。本报告深入探讨了美国对药品和活性药物成分（API）征收的具体关税，并审视了其对美国国内市场和国际贸易的影响。

## 2. Overview of US Pharmaceutical Tariffs
Historically, the WTO Pharmaceutical Agreement of 1994 significantly reduced or eliminated tariffs on a wide range of pharmaceutical products and APIs among its signatories, which include the United States, the European Union, Japan, Canada, Norway, Switzerland, and Macao (China). This agreement aimed to facilitate global trade in medicines and improve access.

However, recent developments and existing trade policies introduce complexities:
- **General US Tariffs:** The Harmonized Tariff Schedule of the United States (HTS), particularly Chapter 30 (Pharmaceutical products) and its Pharmaceutical Appendix, outlines the tariff rates. While many finished pharmaceutical products from WTO agreement signatories are duty-free, specific tariffs can apply to certain categories or from non-signatory countries.
- **Proposed Tariffs:** As of April 2025, there have been discussions and proposals for new tariffs, including a potential 10% global tariff on nearly all goods entering the US. More significantly, there are proposals for higher tariffs (up to 245%) on Chinese active pharmaceutical ingredients (APIs).
- **Tariffs by Other Nations:** It's important to note that some developing nations, notably China and India, which are major producers of APIs and generic drugs, continue to impose import duties on biopharmaceutical products and active ingredients. These can be substantial, with India's basic import duties averaging around ten percent, and potentially reaching 20% or more with additional duties.

## 2. 美国药品关税概述
从历史上看，1994年世贸组织《药品协议》大幅削减或取消了其签署国（包括美国、欧盟、日本、加拿大、挪威、瑞士和中国澳门）之间广泛药品和活性药物成分（API）的关税。该协议旨在促进全球药品贸易并改善可及性。

然而，最近的发展和现有的贸易政策带来了复杂性：
- **美国一般关税：** 《美国协调关税表》（HTS），特别是第30章（药品）及其药品附录，规定了关税税率。尽管来自世贸组织协议签署国的许多成品药免征关税，但特定类别或来自非签署国的药品可能适用特定关税。
- **拟议关税：** 截至2025年4月，已有一些关于新关税的讨论和提案，包括对进入美国的所有商品征收潜在的10%全球关税。更重要的是，有提案对来自中国的活性药物成分（API）征收更高的关税（高达245%）。
- **其他国家关税：** 值得注意的是，一些发展中国家，特别是作为API和仿制药主要生产国的中国和印度，继续对生物制药产品和活性成分征收进口关税。这些关税可能很高，印度基本进口关税平均约为10%，加上额外关税可能达到20%或更高。

### Table 2.1: Summary of Key Pharmaceutical Tariffs and Affected Products/Countries

| Tariff Type/Policy | Affected Products | Countries/Regions of Origin | Impact/Notes |
|---|---|---|---|
| **WTO Pharmaceutical Agreement (1994)** | Finished pharmaceuticals, APIs, certain chemical intermediates | Signatory countries (US, EU, Japan, Canada, Switzerland, etc.) | Eliminated tariffs, promoting free trade in these products. |
| **General US HTS Tariffs (Chapter 30)** | Various pharmaceutical products | Global (subject to specific HTS codes and country of origin) | Rates vary; many products from WTO agreement signatories are duty-free. |
| **Proposed US Global Tariff (April 2025)** | Nearly all goods, including pharmaceuticals | Global | Proposed 10% tariff, potentially increasing import costs. |
| **Proposed US Tariffs on Chinese APIs (April 2025)** | Active Pharmaceutical Ingredients (APIs) | China | Proposed tariffs up to 245%, aiming to reduce reliance on Chinese supply. |
| **Indian Import Duties** | Biopharmaceutical products, active ingredients | Global (imports into India) | Average ~10%, can reach 20%+ with additional duties, increasing cost of imports into India. |
| **Chinese Import Duties** | Biopharmaceutical products, active ingredients | Global (imports into China) | Tariffs exist, impacting cost of imports into China. |

### 表2.1：主要药品关税及受影响产品/国家摘要

| 关税类型/政策 | 受影响产品 | 原产国/地区 | 影响/备注 |
|---|---|---|---|
| **世贸组织《药品协议》（1994）** | 成品药、API、某些化学中间体 | 签署国（美国、欧盟、日本、加拿大、瑞士等） | 取消关税，促进这些产品的自由贸易。 |
| **美国一般协调关税表（HTS）关税（第30章）** | 各种药品 | 全球（受特定HTS编码和原产国限制） | 税率各异；许多来自世贸组织协议签署国的产品免征关税。 |
| **美国拟议全球关税（2025年4月）** | 几乎所有商品，包括药品 | 全球 | 拟议10%关税，可能增加进口成本。 |
| **美国拟议对中国API关税（2025年4月）** | 活性药物成分（API） | 中国 | 拟议关税高达245%，旨在减少对中国供应的依赖。 |
| **印度进口关税** | 生物制药产品、活性成分 | 全球（进口到印度） | 平均约10%，加上额外关税可达20%以上，增加进口到印度的成本。 |
| **中国进口关税** | 生物制药产品、活性成分 | 全球（进口到中国） | 存在关税，影响进口到中国的成本。 |

## 3. Impact on Key Countries and Regions
The impact of these tariffs is multifaceted, affecting both exporting and importing nations.

### United States
- **Increased Medicine Prices:** Academic studies and expert analyses consistently suggest that US pharmaceutical tariffs would likely lead to increased medicine prices for American consumers, insurance companies, and government programs. A 25% ad valorem tariff, for instance, could increase medication costs by approximately $600 per year per US household.
- **Supply Chain Vulnerabilities:** Tariffs are expected to disrupt the complex global pharmaceutical supply chain, potentially leading to shortages of essential medicines, especially critical generic drugs. The US relies heavily on imports for APIs and finished dose forms, making it vulnerable to disruptions caused by tariffs.
- **Disproportionate Impact on Generic Drugs:** Generic medications, largely produced in countries like India and China with already thin profit margins, are particularly vulnerable. Tariffs could lead to significant price hikes and increased risk of shortages for these crucial drugs.

### China and India
As major global suppliers of APIs and generic drugs, China and India would be significantly impacted by increased US tariffs.
- **Reduced Exports to US:** Higher US tariffs on their pharmaceutical products and APIs would likely reduce their export volumes to the US, impacting their pharmaceutical industries.
- **Diversification of Markets:** These countries might seek to diversify their export markets to mitigate the impact of US tariffs.
- **Domestic Industry Protection:** Their own import duties on biopharmaceutical products can protect their domestic industries but also increase the cost of imported raw materials for their pharmaceutical manufacturing.

### European Union, Switzerland, Canada, Mexico, Ireland, Germany
These countries are significant players in the global pharmaceutical trade, both as exporters to the US and as sources of innovation.
- **Trade Flow Adjustments:** While many of these countries are WTO Pharmaceutical Agreement signatories, new general US tariffs could still affect their exports.
- **Supply Chain Re-evaluation:** Companies in these regions might re-evaluate their supply chain strategies in response to US tariff policies, potentially seeking to localize production or diversify sourcing.

## 3. 对主要国家和地区的影响
这些关税的影响是多方面的，影响着出口国和进口国。

### 美国
- **药品价格上涨：** 学术研究和专家分析一致表明，美国药品关税可能导致美国消费者、保险公司和政府项目（如医疗保险）的药品价格上涨。例如，25%的从价关税可能使每个美国家庭每年增加约600美元的药品费用。
- **供应链脆弱性：** 关税预计将扰乱复杂的全球药品供应链，可能导致基本药物，特别是关键仿制药的短缺。美国严重依赖进口API和成品剂型，使其容易受到关税造成的干扰。
- **对仿制药的不成比例影响：** 仿制药主要由印度和中国等利润微薄的国家生产，特别容易受到影响。关税可能导致这些关键药物的价格大幅上涨和短缺风险增加。

### 中国和印度
作为API和仿制药的主要全球供应商，中国和印度将受到美国关税增加的显著影响。
- **对美出口减少：** 美国对其药品和API征收更高的关税可能会减少其对美国的出口量，从而影响其制药业。
- **市场多元化：** 这些国家可能会寻求使其出口市场多元化，以减轻美国关税的影响。
- **国内产业保护：** 它们对生物制药产品征收的进口关税可以保护其国内产业，但也会增加其制药生产所需进口原材料的成本。

### 欧盟、瑞士、加拿大、墨西哥、爱尔兰、德国
这些国家在全球药品贸易中扮演着重要角色，既是美国的出口国，也是创新的来源。
- **贸易流量调整：** 尽管这些国家中有许多是世贸组织《药品协议》的签署国，但新的美国一般关税仍可能影响其出口。
- **供应链重新评估：** 这些地区的公司可能会根据美国关税政策重新评估其供应链战略，可能寻求本地化生产或多元化采购。

## 4. Supply Chain Restructuring
The imposition of tariffs acts as a catalyst for restructuring global pharmaceutical supply chains. Companies are increasingly looking to:
- **Reshoring/Nearshoring:** Bringing production back to the US or to neighboring countries (e.g., Mexico, Canada) to reduce reliance on distant suppliers and mitigate tariff risks.
- **Diversification of Sourcing:** Spreading production and sourcing across multiple countries to reduce dependence on any single region, thereby enhancing supply chain resilience.
- **Increased Domestic Production:** Governments, including the US, are exploring incentives and policies to boost domestic manufacturing of essential medicines and APIs to ensure national security and reduce foreign dependence.

## 4. 供应链重组
关税的实施是重组全球药品供应链的催化剂。公司正越来越多地寻求：
- **回流/近岸外包：** 将生产迁回美国或邻近国家（例如墨西哥、加拿大），以减少对遥远供应商的依赖并降低关税风险。
- **采购多元化：** 将生产和采购分散到多个国家，以减少对任何单一地区的依赖，从而增强供应链弹性。
- **增加国内生产：** 包括美国在内的各国政府正在探索激励措施和政策，以促进基本药物和API的国内生产，以确保国家安全并减少对外国的依赖。

## 5. Consumer and Industry Consequences

### Consumers
- **Higher Costs:** The most direct impact on consumers is the potential for higher medicine prices, making essential drugs less affordable.
- **Reduced Access:** Supply chain disruptions and shortages, exacerbated by tariffs, could limit access to critical medications.

### Pharmaceutical Industry
- **Increased Production Costs:** Tariffs on imported APIs and raw materials increase the cost of manufacturing for pharmaceutical companies, which may be passed on to consumers.
- **Strategic Adjustments:** Companies are forced to make strategic adjustments, including re-evaluating manufacturing locations, sourcing strategies, and investment decisions.
- **Impact on Innovation:** While some argue tariffs could incentivize domestic innovation, others contend that increased costs and market uncertainties could stifle research and development, particularly for smaller companies.

## 5. 消费者和行业影响

### 消费者
- **成本增加：** 对消费者最直接的影响是药品价格可能上涨，使基本药物的可负担性降低。
- **可及性降低：** 供应链中断和短缺，因关税而加剧，可能限制关键药物的可及性。

### 制药业
- **生产成本增加：** 对进口API和原材料征收关税会增加制药公司的生产成本，这可能会转嫁给消费者。
- **战略调整：** 公司被迫进行战略调整，包括重新评估生产地点、采购策略和投资决策。
- **对创新的影响：** 尽管一些人认为关税可以激励国内创新，但另一些人则认为，成本增加和市场不确定性可能会抑制研发，特别是对于小型公司。

## 6. Conclusion and Outlook
US tariffs on pharmaceutical products, whether existing or proposed, have significant implications for global health and the pharmaceutical industry. While the WTO Pharmaceutical Agreement has fostered a largely tariff-free environment for many pharmaceutical products, recent protectionist tendencies and existing tariffs in key manufacturing nations introduce new challenges. The primary concerns revolve around increased medicine prices for consumers, potential drug shortages, and the disruption of established global supply chains.

The long-term outlook suggests a continued push towards supply chain diversification and potentially reshoring of pharmaceutical manufacturing to enhance resilience and reduce geopolitical risks. However, these shifts come with costs that may ultimately be borne by consumers. International cooperation and multilateral agreements remain crucial to ensuring the affordable and equitable access to medicines worldwide.

## 6. 结论与展望
美国对药品征收的关税，无论是现有的还是拟议的，都对全球健康和制药业产生重大影响。尽管世贸组织《药品协议》为许多药品创造了一个基本无关税的环境，但最近的保护主义倾向和主要制造国现有的关税带来了新的挑战。主要担忧集中在消费者药品价格上涨、潜在的药品短缺以及现有全球供应链的中断。

长期展望表明，将继续推动供应链多元化，并可能将药品生产回流，以增强弹性和降低地缘政治风险。然而，这些转变会带来成本，最终可能由消费者承担。国际合作和多边协议对于确保全球药品的可负担性和公平可及性仍然至关重要。

## 7. Appendix: Data Tables and Sources
(This section will be populated with specific data tables and detailed source citations after data analysis.)

### Trade Data Analysis (Simulated)
Based on the general trends identified from academic studies and news reports, the following observations can be inferred regarding trade data:

- **Pre-Tariff Trends:** Prior to the imposition of significant tariffs, there was likely a steady flow of pharmaceutical imports into the US, with a high reliance on countries like China and India for APIs and generic finished products due to cost efficiencies.
- **Post-Tariff Trends:** Following the implementation or proposal of tariffs, it is expected that:
    - **Diversion of Trade:** Some trade might divert away from highly-tariffed countries towards those with lower or no tariffs, or towards domestic production if feasible.
    - **Increased Import Costs:** Even if trade volumes remain similar, the cost of imports for US companies would increase due to the tariffs, which would likely be passed on to consumers.
    - **Shift in Sourcing:** US pharmaceutical companies would likely explore alternative sourcing strategies, potentially leading to a decrease in imports from countries facing high tariffs and an increase from other regions or domestic suppliers.
    - **Impact on Specific Products:** Generic drugs and APIs, with their already thin margins, would be disproportionately affected, potentially leading to a decrease in their import volumes from tariffed countries or a significant increase in their prices.

**Note:** Due to the inability to access real-time, granular trade data from UN Comtrade, US Census Bureau, or Eurostat, this analysis is based on the general economic principles and reported impacts of tariffs on the pharmaceutical sector. A comprehensive report would include detailed statistical tables and graphs illustrating these trends with actual trade figures.

### Synthesis of Findings
- **Economic Burden on Consumers:** The most consistent finding across various sources is the direct economic burden on US consumers through higher medicine prices. This is a critical public health concern, potentially limiting access to essential medications.
- **Supply Chain Fragility Exposed:** Tariffs have highlighted the fragility of global pharmaceutical supply chains, which are highly interconnected and reliant on a few key manufacturing hubs. This has spurred discussions and actions towards greater supply chain resilience and diversification.
- **Geopolitical Tool:** Tariffs are increasingly being used as a geopolitical tool to reduce reliance on specific countries for critical goods, including pharmaceuticals. This has implications for international trade relations and global health security.
- **Innovation vs. Affordability:** There's a tension between the desire to incentivize domestic pharmaceutical innovation through protectionist measures and the need to ensure affordable access to medicines. The current evidence suggests that tariffs primarily increase costs without a clear, immediate benefit to domestic innovation that outweighs the consumer burden.
- **Vulnerability of Generics:** The generic drug market, crucial for affordable healthcare, is particularly susceptible to tariff impacts due to its cost-sensitive nature and globalized production. This could lead to significant public health challenges if shortages or unaffordable prices become widespread.

## 7. 附录：数据表和来源
（本节将在数据分析后填充具体数据表和详细来源引用。）

### 贸易数据分析（模拟）
根据学术研究和新闻报道中确定的总体趋势，可以推断出以下关于贸易数据的观察结果：

- **关税前趋势：** 在征收重大关税之前，药品进口到美国可能保持稳定，由于成本效益，高度依赖中国和印度等国家的API和仿制成品药。
- **关税后趋势：** 在关税实施或提案之后，预计将出现以下情况：
    - **贸易转移：** 一些贸易可能从高关税国家转向关税较低或没有关税的国家，或者在可行的情况下转向国内生产。
    - **进口成本增加：** 即使贸易量保持不变，美国公司的进口成本也会因关税而增加，这很可能会转嫁给消费者。
    - **采购转移：** 美国制药公司可能会探索替代采购策略，可能导致从面临高关税的国家进口减少，并从其他地区或国内供应商进口增加。
    - **对特定产品的影响：** 仿制药和API，由于其利润已经很薄，将受到不成比例的影响，可能导致其从征收关税的国家进口量减少或价格大幅上涨。

**注意：** 由于无法访问来自联合国商品贸易数据库、美国人口普查局或欧盟统计局的实时、细粒度贸易数据，本分析基于关税对制药业的一般经济原则和报告影响。一份全面的报告将包含详细的统计表格和图表，用实际贸易数据说明这些趋势。

### 调查结果综合
- **消费者经济负担：** 各种来源中最一致的发现是美国消费者因药品价格上涨而承受的直接经济负担。这是一个关键的公共卫生问题，可能限制基本药物的可及性。
- **供应链脆弱性暴露：** 关税凸显了全球药品供应链的脆弱性，这些供应链高度互联，并依赖少数几个关键制造中心。这促使人们讨论并采取行动，以增强供应链弹性和多元化。
- **地缘政治工具：** 关税正越来越多地被用作地缘政治工具，以减少对特定国家关键商品（包括药品）的依赖。这对国际贸易关系和全球健康安全具有影响。
- **创新与可负担性：** 通过保护主义措施激励国内制药创新与确保药品可负担性之间存在张力。目前的证据表明，关税主要增加成本，而对国内创新的明确、即时的好处不足以抵消消费者的负担。
- **仿制药的脆弱性：** 仿制药市场对可负担医疗保健至关重要，由于其成本敏感性和全球化生产，特别容易受到关税影响。如果短缺或价格过高变得普遍，这可能导致重大的公共卫生挑战。

